Chemistry:AZD-1390
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H32FN5O2 |
| Molar mass | 477.584 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AZD-1390 is an experimental anticancer drug developed by AstraZeneca that inhibits ataxia telangiectasia mutated (ATM).[1][2][3][4][5][6][7]
References
- ↑ Dexheimer, Thomas S.; Coussens, Nathan P.; Silvers, Thomas; Wright, John; Morris, Joel; Doroshow, James H.; Teicher, Beverly A. (25 August 2023). "Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs". Cancer Research Communications 3 (8): 1648–1661. doi:10.1158/2767-9764.CRC-23-0193. PMID 37637936.
- ↑ Bannik, Kristina; Madas, Balázs; Jarke, Sabrina; Sutter, Andreas; Siemeister, Gerhard; Schatz, Christoph; Mumberg, Dominik; Zitzmann-Kolbe, Sabine (1 December 2021). "DNA repair inhibitors sensitize cells differently to high and low LET radiation". Scientific Reports 11 (1): 23257. doi:10.1038/s41598-021-02719-9. PMID 34853427. Bibcode: 2021NatSR..1123257B.
- ↑ Guha, Lahanya; Kumar, Hemant (November 2023). "Drug Repurposing for Spinal Cord Injury: Progress Towards Therapeutic Intervention for Primary Factors and Secondary Complications". Pharmaceutical Medicine 37 (6): 463–490. doi:10.1007/s40290-023-00499-3. PMID 37698762.
- ↑ Fischer, Thomas; Hartmann, Oliver; Reissland, Michaela; Prieto-Garcia, Cristian; Klann, Kevin; Pahor, Nikolett; Schülein-Völk, Christina; Baluapuri, Apoorva et al. (27 April 2022). "PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy". Cell & Bioscience 12 (1): 50. doi:10.1186/s13578-022-00778-7. PMID 35477555.
- ↑ Qi, Yinliang; Wang, Kun; Long, Bin; Yue, Hao; Wu, Yongshuo; Yang, Dexiao; Tong, Minghui; Shi, Xuan et al. (January 2023). "Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design". European Journal of Medicinal Chemistry 246: 114945. doi:10.1016/j.ejmech.2022.114945. PMID 36462444.
- ↑ Teicher, Beverly A.; Doyle, Austin; Wright, John; Kunos, Charles; Silvers, Thomas; Delosh, Rene; Laudeman, Julie; Reinhart, Russell et al. (15 August 2020). "Abstract 328: DNA damage inhibitors with topotecan in a complex spheroid model in PDM and established cell lines". Cancer Research 80 (16_Supplement): 328. doi:10.1158/1538-7445.AM2020-328.
- ↑ Coussens, Nathan P.; Parchment, Ralph E.; Moscow, Jeffrey A.; Doyle, L. Austin; Delosh, René; Laudeman, Julie; Reinhart, Russell; Ogle, Chad et al. (1 July 2021). "Abstract 1072: Combination screening of DNA damaging agents temozolomide and trabectedin with inhibitors of DNA repair using a complex spheroid model with a panel of patient-derived and established tumor cell lines". Cancer Research 81 (13_Supplement): 1072. doi:10.1158/1538-7445.AM2021-1072.
 |  |
